Aurobindo Pharma Subsidiary Buys Khandelwal Labs' Non-Oncology Business for ₹325 Cr

• Aurobindo Pharma's subsidiary, Auro Pharma Ltd, acquired Khandelwal Laboratories' non-oncology prescription business.
• The all-cash transaction is valued at ₹325 crore, effective January 1, 2026.
• The acquired business includes 23 brands, 67 SKUs, 9 pipeline products, 470 field staff, and a distribution network.
• It recorded a turnover of ₹1,135.3 million and an EBITDA of ₹289.9 million in FY2024-25.
• This acquisition strengthens Auro Pharma's domestic market presence in anti-infective and pain management.

Why It Matters: Auro Pharma expands domestic market presence by acquiring Khandelwal Labs' non-oncology business for ₹325 Cr.